HCW9206试剂也已提交美国食品药品监督管理局。

该公司现在正在寻求HCW9206试剂销售和/或集成到基于CAR-T的制造过程中的商业合作伙伴关系。

HCW Biologics (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on cellular immunotherapy for hematological malignancies, chronic infections and autoimmune diseases, today announced the publication of new preclinical data in the Journal of Immunological Methods demonstrating the potential of HCW9206, the Company’s proprietary ex vivo T cell reagent, to improve the long-term survival of adoptive transfer cells and facilitate durable suppression of malignancies, chronic infections and autoimmune diseases.

HCW生物制剂（NASDAQ：HCWB）是一家临床阶段的生物制药公司，重点是细胞免疫疗法，用于血液学恶性肿瘤，慢性感染和自身免疫性疾病，今天宣布在《免疫方法》中发表了新的抗性方法，以改善了HCW9206206206206206的潜在，该杂志在收养转移细胞的存活，并促进对恶性肿瘤，慢性感染和自身免疫性疾病的持久抑制。

“We are excited to share these preclinical data demonstrating the potential of HCW9206 to enhance the persistence and anti-tumor activity of CAR-T cells in relevant disease models,” said Peter Rhode, Chief Scientific Officer and Vice President Clinical Operations at HCW Biologics. “These findings provide further support for the development of HCW9206 as a valuable addition to CAR-T manufacturing processes.”

“我们很高兴共享这些临床前数据，证明了HCW9206在相关疾病模型中增强CAR-T细胞的持久性和抗肿瘤活性的潜力。” “这些发现为HCW9206的开发提供了进一步的支持，这是对CAR-T制造过程的宝贵补充。”

In a preclinical model of triple-negative breast cancer, CAR-T cells displayed poor persistence and limited anti-tumor activity. However, the introduction of HCW9206 led to a significant improvement in CAR-T cell persistence, resulting in complete tumor regression and long-term survival. Moreover, the combination of CAR-T cells with HCW9206 effectively suppressed tumor growth and led to the survival of all treated animals, while untreated animals succumbed to cancer progression.

在三阴性乳腺癌的临床前模型中，CAR-T细胞的持久性较差和抗肿瘤活性有限。但是，HCW9206的引入导致CAR-T细胞持久性的显着改善，从而导致肿瘤的完全消退和长期生存。此外，CAR-T细胞与HCW9206的组合有效地抑制了肿瘤的生长，并导致了所有治疗的动物的存活，而未经治疗的动物则屈服于癌症的进展。

Furthermore, in a preclinical model of HIV infection, CAR-T cells treated with HCW9206 exhibited superior persistence and viral suppression compared to untreated CAR-T cells. This finding suggests that HCW9206 could be instrumental in enhancing the efficacy of adoptive T cell transfer for the treatment of chronic infections.

此外，与未经治疗的CAR-T细胞相比，用HCW9206处理的HCW9206治疗的CAR-T细胞表现出优越的持久性和病毒抑制。这一发现表明，HCW9206可能有助于增强收养T细胞转移治疗慢性感染的功效。

Finally, in a preclinical model of rheumatoid arthritis, CAR-T cells treated with HCW9206 displayed reduced differentiation into memory stem cells and a lower expression of pro-inflammatory cytokines, indicating a potential reduction in the incidence and severity of autoimmune reactions.

最后，在类风湿关节炎的临床前模型中，用HCW9206处理的CAR-T细胞显示出分化减少到记忆干细胞中，促炎细胞因子的表达较低，表明自动免疫反应的发生率和严重程度可能降低。

The ex vivo reagent has also been filed with the US Food and Drug Administration. The Company is now seeking commercial partnerships for HCW9206 reagent sale and/or integration into CAR-T based manufacturing processes.

体内试剂也已提交给美国食品和药物管理局。该公司现在正在寻求HCW9206试剂销售和/或集成到基于CAR-T的制造过程中的商业合作伙伴关系。

About HCW Biologics

关于HCW生物制剂

HCW Biologics (Nasdaq: HCWB) is a clinical-stage biopharmaceutical company developing cellular immunotherapies for hematological malignancies, chronic infections and autoimmune diseases. The Company’s mission is to create best-in-class immuno-modulating therapies that could transform the lives of patients.

HCW Biologics（NASDAQ：HCWB）是一家临床阶段的生物制药公司，开发用于血液恶性肿瘤，慢性感染和自身免疫性疾病的细胞免疫疗法。该公司的任务是创建一流的免疫调节疗法，以改变患者的生活。

The Company’s programs are based on its proprietary iPSC-derived immune cell platform, which enables the generation of homogenous and scalable cell populations with defined properties. HCW Biologics is currently developing a portfolio of programs targeting triple-negative breast cancer, HIV infection and rheumatoid arthritis.

该公司的计划基于其专有IPSC衍生的免疫细胞平台，该平台可以生成具有定义性能的同质和可扩展的细胞群体。 HCW Biologics目前正在开发针对三阴性乳腺癌，HIV感染和类风湿关节炎的程序组合。

HCW Biologics is headquartered in Rockville, Maryland.

HCW Biologics总部位于马里兰州罗克维尔。

Company Contact:

公司联系人：

Chief Scientific Officer and Vice President Clinical Operations

首席科学官兼副总裁临床行动

HCW Biologics Inc.

peterrhode@hcwbiologics.com